T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Insteel Industries
IIIN
$634M
| $745K | ﹤0.01% |
23,497
+883
| +4% | +$28.8K |
|
2202
CNA Financial
CNA
$13.8B
| $742K | ﹤0.01% |
15,536
+539
| +4% | +$24.8K |
|
2203
Hippo Holdings
HIPO
$869M
| $740K | ﹤0.01% |
24,588
+834
| +4% | +$27.9K |
|
2204
CareDx
CDNA
$2.45B
| $739K | ﹤0.01% |
39,218
+711
| +2% | +$11.9K |
|
|
TRST
2205
Trustco Bank Corp NY
TRST
$971M
| $739K | ﹤0.01% |
17,865
-2,296
| -11% | -$91.5K |
|
2206
Liquidity Services
LQDT
$1.35B
| $737K | ﹤0.01% |
24,284
-4,240
| -15% | -$114K |
|
2207
Under Armour
UAA
$2.3B
| $737K | ﹤0.01% |
148,248
+4,698
| +3% | +$21.7K |
|
|
AAMI
2208
Acadian Asset Management
AAMI
$3.31B
| $737K | ﹤0.01% |
15,667
+1,392
| +10% | +$64.1K |
|
|
NPKI
2209
NPK International
NPKI
$1.18B
| $736K | ﹤0.01% |
61,736
+3,181
| +5% | +$38.8K |
|
2210
OneSpan
OSPN
$624M
| $733K | ﹤0.01% |
57,019
+8,256
| +17% | +$112K |
|
2211
SI-BONE Inc
SIBN
$849M
| $733K | ﹤0.01% |
37,159
+1,459
| +4% | +$25.3K |
|
2212
Blackstone Secured Lending
BXSL
$5.83B
| $729K | ﹤0.01% |
27,660
-2,602
| -9% | -$69.8K |
|
2213
Energy Recovery
ERII
$399M
| $725K | ﹤0.01% |
53,701
+5,798
| +12% | +$87.9K |
|
2214
Hovnanian Enterprises
HOV
$799M
| $725K | ﹤0.01% |
7,426
-158
| -2% | -$18.6K |
|
2215
Lightpath Technologies
LPTH
$824M
| $725K | ﹤0.01% |
67,053
-6,600
| -9% | -$53.5K |
|
2216
Fulcrum Therapeutics
FULC
$283M
| $722K | ﹤0.01% |
63,760
-2,132
| -3% | -$21.7K |
|
2217
Helen of Troy
HELE
$699M
| $722K | ﹤0.01% |
33,958
+9,267
| +38% | +$189K |
|
2218
BioLife Solutions
BLFS
$1.72B
| $721K | ﹤0.01% |
29,783
+4,014
| +16% | +$105K |
|
2219
Cracker Barrel
CBRL
$1.31B
| $721K | ﹤0.01% |
28,370
+3,707
| +15% | +$119K |
|
2220
BBVA Argentina
BBAR
$3.27B
| $720K | ﹤0.01% |
39,830
+8,280
| +26% | +$119K |
|
2221
Hamilton Insurance Group
HG
$2.32B
| $719K | ﹤0.01% |
25,759
+1,190
| +5% | +$30.9K |
|
2222
Kearny Financial
KRNY
$604M
| $716K | ﹤0.01% |
96,507
| – | – |
|
|
AGNT
2223
AGNT Inc
AGNT
$752M
| $713K | ﹤0.01% |
78,740
-395,633
| -83% | -$4.18M |
|
2224
BrightView Holdings
BV
$1.08B
| $711K | ﹤0.01% |
56,066
+2,798
| +5% | +$35.5K |
|
2225
Washington Trust Bancorp
WASH
$767M
| $710K | ﹤0.01% |
24,007
+6,846
| +40% | +$195K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.